Mesenchymal stem cells (MSCs) possess potent and broad immunosuppressive capabilities, and have shown promise in clinical trials treating many inflammatory diseases. Previous studies have found that MSCs inhibit dendritic cell, T-cell, and B-cell activities in the adaptive immunity; however, whether MSCs inhibit complement in the innate immunity, and if so, by which mechanism, have not been established. In this report, we found that MSCs constitutively secrete factor H, which potently inhibits complement activation. Depletion of factor H in the MSC-conditioned serum-free media abolishes their complement inhibitory activities. In addition, production of factor H by MSCs is augmented by inflammatory cytokines TNF-α and interferon-γ (IFN-γ) in dose- and time-dependent manners, while IL-6 does not have a significant effect. Furthermore, the factor H production from MSCs is significantly suppressed by the prostaglandin E2 (PGE2) synthesis inhibitor indomethacin and the indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyl-d-tryptophan (1-MT), both of which inhibitors are known to efficiently dampen MSCs immunosuppressive activity. These results indicate that MSCs inhibit complement activation by producing factor H, which could be another mechanism underlying MSCs broad immunosuppres-sive capabilities.
Get full access to this article
View all access options for this article.
References
1.
SongWC, SarriasMR, LambrisJD. 2000. Complement and innate immunity. Immunopharmacology, 49:187–198.
2.
MuntheE, HoyeraalHM, FrolandSS, MellbyeOJ, KassE, NatvigJB. 1975. Evidence for complement activation by the alternate pathway in the arthritis of hypogammaglobulinemic patients. Rheumatology, 6:43–51.
3.
RuddyS, AustenKF. 1975. Activation of the complement and properdin systems in rheumatoid arthritis. Ann N Y Acad Sci, 256:96–104.
4.
SundsmoJS, PapinRA, WoodL, HiraniS, WaldeckN, BuckinghamB, KershnarA, AscherM, CharlesMA. 1985. Complement activation in type 1 human diabetes. Clin Immunol Immunopathol, 35:211–225.
5.
RadilloO, NoceraA, LepriniA, BarocciS, MollnesTE, PoceccoM, PausaM, ValenteU, BetterleC, TedescoF. 1996. Complement-fixing islet cell antibodies in type-1 diabetes can trigger the assembly of the terminal complement complex on human islet cells and are potentially cytotoxic. Clin Immunol Immunopathol, 79:217–223.
6.
LennonVA, LambertEH. 1981. Monoclonal autoantibodies to acetylcholine receptors: evidence for a dominant idiotype and requirement of complement for pathogenicity. Ann N Y Acad Sci, 377:77–96.
PerrinLH, LambertPH, MiescherPA. 1975. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest, 56:165–176.
10.
ChrupcalaM, PomerS, StaehlerG, WaldherrR, KirschfinkC. 1994. Prolongation of discordant renal xenograft survival by depletion of complement. Comparative effects of systemically administered cobra venom factor and soluble complement receptor type 1 in a guinea-pig to rat model. Transpl Int, 7,Suppl 1:S650–S653.
11.
SvalanderC, HedmanL, NybergG, EggertsenG, NilssonB, NilssonU. 1992. Local C3 activation and macrophage accumulation in renal allografts with early vascular rejection. Transplant Proc, 24:305–306.
12.
ZipfelPF, HellwageJ, FrieseMA, HegasyG, JokirantaST, MeriS. 1999. Factor H and disease: a complement regulator affects vital body functions. Mol Immunol, 36:241–248.
13.
WhaleyK, RuddyS. 1976. Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med, 144:1147–1163.
14.
KazatchkineMD, FearonDT, AustenKF. 1979. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol, 122:75–81.
15.
WeilerJM, DahaMR, AustenKF, FearonDT. 1976. Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci USA, 73:3268–3272.
16.
FijenCA, KuijperEJ, Te BulteM, van de HeuvelMM, HoldrinetAC, SimRB, DahaMR, DankertJ. 1996. Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol, 105:511–516.
17.
NielsenHE, ChristensenKC, KochC, ThomsenBS, HeegaardNH, Tranum-JensenJ. 1989. Hereditary, complete deficiency of complement factor H associated with recurrent meningococcal disease. Scand J Immunol, 30:711–718.
18.
AultBH, SchmidtBZ, FowlerNL, KashtanCE, AhmedAE, VogtBA, ColtenHR. 1997. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem, 272:25168–25175.
19.
CaplanAI. 2009. Why are MSCs therapeutic? New data: new insight. J Pathol, 217:318–324.
JiangXX, ZhangY, LiuB, ZhangSX, WuY, YuXD, MaoN. 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105:4120–4126.
22.
KramperaM, GlennieS, DysonJ, ScottD, LaylorR, SimpsonE, DazziF. 2003. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101:3722–3729.
ZipfelPF, EdeyM, HeinenS, JózsiM, RichterH, MisselwitzJ, HoppeB, RoutledgeD, StrainL, HughesAE, GoodshipJA, LichtC, GoodshipTH, SkerkaC. 2007. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet, 3:e41.
25.
HourcadeDE, WagnerLM, OglesbyTJ. 1995. Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis. J Biol Chem, 270:19716–19722.
26.
SambrookJ, FritschEF, ManiatisT. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY.
27.
BrooimansRA, HiemstraPS, van der ArkAA, SimRB, van EsLA, DahaMR. 1989. Biosynthesis of complement factor H by human umbilical vein endothelial cells. Regulation by T cell growth factor and IFN-gamma. J Immunol, 142:2024–2030.
28.
GiesekeF, SchüttB, ViebahnS, KoscielniakE, FriedrichW, HandgretingerR, MüllerI. 2007. Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood, 110:2197–2200.
29.
KlosA, TennerAJ, JohswichKO, AgerRR, ReisES, KöhlJ. 2009. The role of the anaphylatoxins in health and disease. Mol Immunol, 46:2753–2766.
30.
YingL, KatzY, SchlesingerM, CarmiR, ShalevH, HaiderN, BeckG, SheffieldVC, LandauD. 1999. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet, 65:1538–1546.
31.
Pérez-CaballeroD, González-RubioC, GallardoME, VeraM, López-TrascasaM, Rodríguez de CórdobaS, Sánchez-CorralP. 2001. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet, 68:478–484.
32.
Abrera-AbeledaMA, NishimuraC, SmithJL, SethiS, McRaeJL, MurphyBF, SilvestriG, SkerkaC, JózsiM, ZipfelPF, HagemanGS, SmithRJ. 2006. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)J Med Genet, 43:582–589.
33.
Dragon-DureyMA, Frémeaux-BacchiV, LoiratC, BlouinJ, NiaudetP, DeschenesG, CoppoP, Herman FridmanW, WeissL. 2004. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol, 15:787–795.
34.
EdwardsAO, RitterRIII, AbelKJ, ManningA, PanhuysenC, FarrerLA. 2005. Complement factor H polymorphism and age-related macular degeneration. Science, 308:421–424.
BrooimansRA, van der ArkAA, BuurmanWA, van EsLA, DahaMR. 1990. Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-gamma and IL-1. J Immunol, 144:3835–3840.
37.
GerritsmaJS, GerritsenAF, De LeyM, van EsLA, DahaMR. 1997. Interferon-gamma induces biosynthesis of complement components C2, C4 and factor H by human proximal tubular epithelial cells. Cytokine, 9:276–283.
38.
TrounsonA. 2009. New perspectives in human stem cell therapeutic research. BMC Med, 7:29.
39.
TseWT, PendletonJD, BeyerWM, EgalkaMC, GuinanEC. 2003. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 75:389–397.
40.
MeiselR, ZibertA, LaryeaM, GöbelU, DäubenerW, DillooD. 2004. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103:4619–4621.
41.
RasmussonI, RingdénO, SundbergB, Le BlancK. 2005. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res, 305:33–41.
42.
VargaL, PorosA, PuskásE, PányaA, KramerJ, GyódiE, FüstG. 1995. Clinical significance of longitudinal complement measurements in recipients of bone marrow transplant. Bone Marrow Transplant, 15:509–514.
43.
TsoiMS, StorbR, JonesE, WeidenPL, ShulmanH, WitherspoonR, AtkinsonK, ThomasED. 1978. Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol, 120:1485–1492.
44.
CaraherEM, NewsholmeP. 1997. Complement is involved in the mechanism of IDDM serum induced pancreatic beta-cell cytotoxicity. Biochem Soc Trans, 25:319S.
45.
OkrojM, HeinegardD, HolmdahlR, BlomAM. 2007. Rheumatoid arthritis and the complement system. Ann Med, 39:517–530.
SacksSH, ZhouW. 2005. Allograft rejection: effect of local synthesis of complement. Springer Semin Immunopathol, 27:332–344.
48.
FrieseMA, HellwageJ, JokirantaTS, MeriS, Müller-QuernheimHJ, PeterHH, EibelH, ZipfelPF. 2000. Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA)Clin Exp Immunol, 121:406–415.
49.
FrieseMA, ManuelianT, JunnikkalaS, HellwageJ, MeriS, PeterHH, GordonDL, EibelH, ZipfelPF. 2003. Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol, 132:485–495.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
